ストックスクリーナーアプリを入手
1.46
3.55%
0.05
プレマーケット:
1.46
前日終値:
$1.41
開ける：
$1.41
24時間の取引高:
69,546
Relative Volume:
0.09
時価総額：
$14.73M
収益：
$960.60K
当期純損益:
$-7.10M
株価収益率:
-0.1931
EPS:
-7.56
ネットキャッシュフロー:
$-8.00M
1週間 パフォーマンス:
+8.96%
1か月 パフォーマンス:
-9.32%
6か月 パフォーマンス:
+30.36%
1年 パフォーマンス:
-59.33%
1日の値動き範囲:
$1.4074
$1.47
1週間の範囲:
$1.3401
$1.49
52週間の値動き範囲:
$1.09
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
SNGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.46 | 14.22M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-07-28 | ダウングレード | Dawson James | Buy → Neutral |
| 2018-01-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 繰り返されました | Maxim Group | Buy |
| 2017-07-17 | 開始されました | H.C. Wainwright | Buy |
Soligenix Inc (SNGX) 最新ニュース
Soligenix Completes Key Phase 2 Psoriasis Trial, Setting the Stage for SGX302 Data - TipRanks
Ideas Watch: Can Soligenix Inc stock double in next 5 yearsWeekly Trend Recap & Verified Momentum Stock Watchlist - moha.gov.vn
What drives Soligenix Inc DOA0 stock priceMerger & Acquisition Updates & Buy Sell Timing Alerts - earlytimes.in
Tech Rally: Is Soligenix Inc stock overvalued by current metricsLong Setup & Daily Technical Forecast Reports - moha.gov.vn
Soligenix (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat - Digital Journal
SNGX: Positive Results for Phase 2a Trial in Psoriasis - Research Tree
Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease - Indian Pharma Post
Gains Recap: Will Soligenix Inc. (DOA0) stock issue positive guidanceJuly 2025 Market Mood & Free Verified High Yield Trade Plans - Улправда
Is Soligenix Inc. stock cheap at current valuationQuarterly Profit Summary & Smart Money Movement Tracker - Улправда
Alliance Global Partners Sticks to Its Buy Rating for Soligenix (SNGX) - The Globe and Mail
Will Soligenix Inc. (DOA0) stock issue positive guidanceJuly 2025 Summary & Growth Focused Entry Point Reports - Улправда
Institution Moves: Will Soligenix Inc. (DOA0) stock beat Nasdaq index returnsJuly 2025 PostEarnings & Daily Profit Maximizing Trade Tips - DonanımHaber
How Soligenix Inc. stock benefits from strong dollarJuly 2025 Pullbacks & Capital Efficiency Focused Ideas - DonanımHaber
Soligenix (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behcet's Disease - Digital Journal
Soligenix reports positive results from SGX945 trial for Behçet’s disease By Investing.com - Investing.com Nigeria
Soligenix (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease - Barchart.com
Soligenix, Inc. Announces Positive Clinical Results from Phase 2 Trial of Sgx945 for the Treatment of Behcet's Disease Published in Rheumatology - marketscreener.com
Soligenix shares jump on encouraging data for Behçet’s disease therapy - MSN
Soligenix stock rises after positive Behçet’s Disease treatment data By Investing.com - Investing.com Nigeria
Soligenix stock rises after positive Behçet’s Disease treatment data - Investing.com India
Soligenix (SNGX) Shows Promising Results in Phase 2a Behcet's Di - GuruFocus
Soligenix reports positive results from SGX945 trial for Behçet’s disease - Investing.com
Positive Clinical Results from Phase 2 Trial of SGX945 for the T - GuruFocus
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behcet's Disease Published in Rheumatology (Oxford) - Finviz
Positive clinical results from phase 2 trial of SGX945 - marketscreener.com
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) - Fidelity
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) – Company AnnouncementFT.com - Financial Times
Market Recap: How strong is Soligenix Inc. stock balance sheetChart Signals & Verified Swing Trading Watchlists - Улправда
Soligenix (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis - Digital Journal
Soligenix reports positive results from psoriasis gel treatment trial By Investing.com - Investing.com Nigeria
Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel - Benzinga
Soligenix Announces Top-line Results of the Phase 2a Study of SG - GuruFocus
Soligenix reports positive results from psoriasis gel treatment trial - Investing.com
Soligenix announces top-line results of the phase 2a study of SGX302 - marketscreener.com
Soligenix (SNGX) Reports Promising Phase 2a Results for Psoriasis Treatment - GuruFocus
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis – Company AnnouncementFT.com - Financial Times
[Form 4] SOLIGENIX, INC. Insider Trading Activity - Stock Titan
Soligenix (NASDAQ: SNGX) awards CFO 100,000 options at $ 1.63 strike - Stock Titan
Soligenix (NASDAQ: SNGX) Featured in NetworkNewsAudio APR on Urgent Need for Rare Disease Therapies - Digital Journal
Soligenix’s HyBryte Therapy Advances as Rare Disease Treatment Gap Grows - citybuzz
NetworkNewsAudio Announces Audio Press Release (APR) on Final Confirmatory Clinical Study Being Done for Treatment of Rare Disease - The Manila Times
NetworkNewsAudio Announces Audio Press Release (APR) on - GlobeNewswire
Soligenix (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone - Digital Journal
Soligenix (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies - Digital Journal
Soligenix Featured in Editorial on Growing Need for Rare Disease Therapies - citybuzz
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad - GlobeNewswire
Why Soligenix Inc. (DOA0) stock signals breakout potentialInflation Watch & Fast Exit and Entry Strategy Plans - Newser
How Soligenix Inc. (DOA) stock expands through international marketsStop Loss & Weekly High Return Opportunities - Newser
Soligenix Inc (SNGX) 財務データ
収益
当期純利益
現金流量
EPS
28.63%
大文字化:
|
ボリューム (24 時間):